Trade Report: Today, ANI Pharmaceuticals Inc. (NASDAQ:ANIP) Given Consensus Rating of “Buy” by Analysts

Today, ANI Pharmaceuticals Inc. (NASDAQ:ANIP) Given Consensus Rating of “Buy” by Analysts

Shares of ANI Pharmaceuticals Inc. (NASDAQ:ANIP) have earned an average rating of “Buy” from the nine research firms that are covering the company. Two investment analysts have rated the stock with a hold recommendation, five have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $65.17.

ANIP has been the subject of a number of recent analyst reports. Zacks Investment Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $67.00 target price for the company in a research report on Wednesday, July 20th. Raymond James Financial Inc. started coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, June 22nd. They set a “strong-buy” rating and a $68.00 price objective for the company. Citigroup Inc. downgraded shares of ANI Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $49.00 price objective for the company. in a research report on Friday, July 8th. They noted that the move was a valuation call. TheStreet raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, August 26th. Finally, Guggenheim reaffirmed a “buy” rating and set a $80.00 price objective (up previously from $65.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 5th.

In related news, insider Arthur Przybyl sold 37,455 shares of the stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $66.97, for a total value of $2,508,361.35. Following the transaction, the insider now directly owns 200,788 shares in the company, valued at approximately $13,446,772.36. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Robert W. Schrepfer sold 12,500 shares of the stock in a transaction on Monday, August 8th. The stock was sold at an average price of $67.06, for a total value of $838,250.00. Following the completion of the transaction, the vice president now owns 17,362 shares in the company, valued at $1,164,295.72. The disclosure for this sale can be found here. 31.60% of the stock is owned by corporate insiders.

Institutional investors have recently modified their holdings of the company. BNP Paribas Arbitrage SA boosted its position in shares of ANI Pharmaceuticals by 94.9% in the second quarter. BNP Paribas Arbitrage SA now owns 2,364 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 1,151 shares during the period. Bank of Montreal Can bought a new position in shares of ANI Pharmaceuticals during the second quarter valued at $177,000. Thrivent Financial for Lutherans bought a new position in shares of ANI Pharmaceuticals during the second quarter valued at $204,000. Arizona State Retirement System bought a new position in shares of ANI Pharmaceuticals during the second quarter valued at $219,000. Finally, BlackRock Advisors LLC boosted its position in shares of ANI Pharmaceuticals by 6.1% in the second quarter. BlackRock Advisors LLC now owns 3,975 shares of the specialty pharmaceutical company’s stock valued at $222,000 after buying an additional 230 shares during the period. Institutional investors own 48.74% of the company’s stock.

Shares of ANI Pharmaceuticals (NASDAQ:ANIP) traded down 1.29% during mid-day trading on Thursday, hitting $68.07. 111,917 shares of the stock were exchanged. The stock’s 50 day moving average price is $64.50 and its 200-day moving average price is $54.54. ANI Pharmaceuticals has a 12-month low of $26.80 and a 12-month high of $70.92. The stock has a market capitalization of $783.76 million, a P/E ratio of 79.99 and a beta of 2.92.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Thursday, August 4th. The specialty pharmaceutical company reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.34. The business earned $31.30 million during the quarter, compared to the consensus estimate of $27.63 million. ANI Pharmaceuticals had a net margin of 11.02% and a return on equity of 20.12%. The company’s revenue for the quarter was up 60.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.55 EPS. On average, equities research analysts expect that ANI Pharmaceuticals will post $4.12 EPS for the current fiscal year.

Related posts

Leave a Comment